Literature DB >> 7529450

Prediction of prostate cancer volume using prostate-specific antigen levels, transrectal ultrasound, and systematic sextant biopsies.

M K Terris1, D J Haney, I M Johnstone, J E McNeal, T A Stamey.   

Abstract

OBJECTIVES: Prostate-specific antigen (PSA) levels, transrectal ultrasound, and systematic sextant biopsies have each shown limited ability to predict prostate cancer volume. In combination, these studies may allow more accurate estimation of volume and prognosis.
METHODS: One hundred twenty-four patients were evaluated prior to radical prostatectomy. Interactive stepwise multiple regression and separate logistic regression analysis were performed for prediction of prostate cancer volume and volume range.
RESULTS: The cancer volumes calculated correlated with the volumes in the radical prostatectomy specimens with R2 of 0.76. Cancers were predicted to be in the volume range associated with poor prognosis (more than 12 cc) or clinically insignificant cancer (less than 1.0 cc) with bias corrected error rates of 5.3% and 10%, respectively.
CONCLUSIONS: The formula for prediction of cancer volume correlates well with actual cancer volume in 92 patients but is not adequate to predict volume for an individual patient. The formulas for prediction of volume range show promising predictive ability and may be useful if the extent of disease is unclear.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7529450     DOI: 10.1016/s0090-4295(95)96858-x

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  10 in total

1.  Screening for prostate cancer today.

Authors:  J N Kabalin
Journal:  West J Med       Date:  1995-03

2.  Biopsy diagnosis of prostatic cancer--current areas of concern.

Authors:  M R Feneley; M C Parkinson
Journal:  J Clin Pathol       Date:  1997-04       Impact factor: 3.411

Review 3.  Concomitant bladder cancer and prostate cancer: challenges and controversies.

Authors:  Antonio Lopez-Beltran; Liang Cheng; Francesco Montorsi; Maria Scarpelli; Maria R Raspollini; Rodolfo Montironi
Journal:  Nat Rev Urol       Date:  2017-08-16       Impact factor: 14.432

4.  Does screening for prostate cancer identify clinically important disease?

Authors:  M R Feneley
Journal:  Ann R Coll Surg Engl       Date:  1999-05       Impact factor: 1.891

5.  A quantitative model for the dynamics of serum prostate-specific antigen as a marker for cancerous growth: an explanation for a medical anomaly.

Authors:  K R Swanson; L D True; D W Lin; K R Buhler; R Vessella; J D Murray
Journal:  Am J Pathol       Date:  2001-06       Impact factor: 4.307

Review 6.  Stage T1c prostate cancer: defining the appropriate staging evaluation and the role for pelvic lymphadenectomy.

Authors:  M C Beduschi; R Beduschi; J E Oesterling
Journal:  World J Urol       Date:  1997       Impact factor: 4.226

7.  Prostate Cancer - Old Problems and New Approaches. (Part II. Diagnostic and Prognostic Markers, Pathology and Biological Aspects).

Authors:  Kenneth V Honn; Amer Aref; Yong Q Chen; Michael L Cher; John D Crissman; Jeffrey D Forman; Xiang Gao; David Grignon; Maha Hussain; Arthur T Porter; Edson J Pontes; Bruce Redman; Wael Sakr; Richard Severson; Dean G Tang; David P Wood
Journal:  Pathol Oncol Res       Date:  1996       Impact factor: 3.201

8.  Informatics in radiology: comparison of logistic regression and artificial neural network models in breast cancer risk estimation.

Authors:  Turgay Ayer; Jagpreet Chhatwal; Oguzhan Alagoz; Charles E Kahn; Ryan W Woods; Elizabeth S Burnside
Journal:  Radiographics       Date:  2009-11-09       Impact factor: 5.333

Review 9.  Tumor focality in prostate cancer: implications for focal therapy.

Authors:  Markos Karavitakis; Hashim U Ahmed; Paul D Abel; Steven Hazell; Mathias H Winkler
Journal:  Nat Rev Clin Oncol       Date:  2010-11-23       Impact factor: 66.675

10.  Prognostic factors in prostate cancer.

Authors:  A Buhmeida; S Pyrhönen; M Laato; Y Collan
Journal:  Diagn Pathol       Date:  2006-04-03       Impact factor: 2.644

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.